bioAffinity Technologies, Inc. has announced an increase in the amount of common stock it plans to sell through its existing sales agreement. The company filed a prospectus supplement on November 3, 2026, to raise up to $5,228,226 in additional funding.

This filing is significant as it reflects bioAffinity's efforts to bolster its financial resources amidst the competitive landscape of the commercial physical and biological research industry. The company is looking to enhance its capital position to support ongoing operations and potential growth initiatives.

Background

bioAffinity Technologies, Inc. is categorized under the Standard Industrial Classification (SIC) code 8731, which pertains to services in commercial physical and biological research. The company trades on the Nasdaq under the ticker symbols BIAF and BIAFW. Its recent filings include a series of prospectus supplements and registration statements aimed at raising capital.

What the Filing Says

The prospectus supplement corrects a typographical error from a previous filing dated November 2, 2026. It states, "This prospectus supplement supplements and amends and restates the Prospectus Supplement dated May 27, 2025, filed as part of our registration statement on Form S-3 (File No. 333-275608)." The filing indicates that bioAffinity has already sold 114,672 shares of common stock for gross proceeds of approximately $1,300,000 under the sales agreement.

Impact

This increase in the common stock offering may affect a variety of stakeholders, including current and potential investors, as well as competitors in the commercial research sector. The move is designed to provide bioAffinity with additional capital to continue its operations and expand its research capabilities.

What's Next

The filing does not specify what happens next, but it indicates that the company will continue to sell shares under the sales agreement with WallachBeth Capital LLC, acting as the sales agent.